DiaMedica Therapeutics Inc.
DMAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19,057 | $13,110 | $7,839 | $8,765 |
| G&A Expenses | $7,431 | $7,961 | $6,059 | $4,881 |
| SG&A Expenses | $7,624 | $8,157 | $6,162 | $4,881 |
| Sales & Mktg Exp. | $193 | $196 | $103 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,681 | $21,267 | $14,001 | $13,646 |
| Operating Income | -$26,681 | -$21,267 | -$14,001 | -$13,646 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,267 | $1,929 | $353 | $82 |
| Pre-Tax Income | -$24,414 | -$19,338 | -$13,648 | -$13,564 |
| Tax Expense | $30 | $43 | $28 | $28 |
| Net Income | -$24,444 | -$19,381 | -$13,676 | -$13,592 |
| % Margin | – | – | – | – |
| EPS | -0.6 | -0.6 | -0.52 | -0.65 |
| % Growth | 0% | -15.4% | 20% | – |
| EPS Diluted | -0.6 | -0.6 | -0.52 | -0.65 |
| Weighted Avg Shares Out | 40,405 | 32,566 | 26,443 | 20,773 |
| Weighted Avg Shares Out Dil | 40,405 | 32,567 | 26,443 | 20,773 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,301 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $39 | $30 | $25 | $24 |
| EBITDA | -$26,642 | -$21,237 | -$13,976 | -$13,622 |
| % Margin | – | – | – | – |